Immediate Impact
2 standout
Citing Papers
Bimetallic Single-Atom Nanozyme-Based Electrochemical-Photothermal Dual-Function Portable Immunoassay with Smartphone Imaging
2024 Standout
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
2023 Standout
Works of Eric Lander being referenced
Using theHER2/CEP17FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
2022
A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Eric Lander | 25 | 20 | 13 | 30 | 9 | 54 | |
| Hong Yu | 22 | 27 | 13 | 25 | 11 | 67 | |
| Fabiana Sousa | 31 | 24 | 8 | 18 | 8 | 52 | |
| Petra Flygare | 34 | 37 | 14 | 23 | 7 | 70 | |
| G Wagner | 21 | 13 | 7 | 16 | 8 | 56 | |
| Danny Orabi | 7 | 23 | 11 | 28 | 9 | 86 | |
| Maria Vilarino-Varela | 21 | 21 | 13 | 31 | 7 | 68 | |
| Gustavo Andreazza Laporte | 9 | 20 | 8 | 21 | 13 | 53 | |
| Srushti Shah | 63 | 29 | 14 | 28 | 11 | 74 | |
| Adam Pennycuick | 28 | 13 | 16 | 32 | 9 | 75 | |
| West Ab | 12 | 20 | 4 | 28 | 7 | 171 |
All Works
Login with ORCID to disown or claim papers
Loading papers...